Fig. 3
From: L1CAM promotes ovarian cancer stemness and tumor initiation via FGFR1/SRC/STAT3 signaling
L1CAM confers chemoresistance and is a druggable target. (A) L1CAM-transduced Ov90 cells were treated with different doses of paclitaxel and subjected to sphere formation assay. (B) SFE assay in OVCAR3 cells treated with the monoclonal neutralizing antibody CE7 (20 μg/ml). (C) Three different primary ovarian cancer samples (OC6, OC7 and OC8) were treated with the neutralizing antibody CE7 (20 μg/ml) and subjected to an SFE assay. For each analysis, data are expressed as means ± SEM from three independent experiments. Comparisons between experimental groups were done with two-sided Student’s t-tests; *p < 0.05, ***p < 0.001; ns = not significant